2025-2026流感季儿童灭活与减毒活流感疫苗效果评估
日本基于2013/14季起持续监测,在2025/26季以K亚分支A(H3N2)流行为主时,采用检测阴性设计评估16家医院1033名住院发热儿童。结果显示灭活疫苗对甲型流感调整VE为43%(95%CI:15-62),减毒活疫苗为81%(95%CI:15-96),但对乙型流感无显著保护。
要点
- 灭活疫苗对甲型流感调整VE为43%(95%CI:15-62)。
- 减毒活疫苗对甲型流感调整VE为81%(95%CI:15-96),但接种人数较少。
- 两种疫苗对乙型流感均未观察到显著保护。
核心结论
- 尽管流行 genetically distinct 的甲型流感病毒,两种疫苗对甲型流感仍保持有效。
- 对乙型流感未观察到显著保护。
研究设计与样本
- 检测阴性设计,纳入16家医院门诊流感检测的住院发热儿童。
- 共1033名参与者,检测阴性对照中灭活疫苗接种率38%(274/723),减毒活疫苗接种率5%(35/723)。
主要发现
- 灭活疫苗对甲型流感调整VE为43%(95%CI:15-62,N=922)。
- 减毒活疫苗对甲型流感调整VE为81%(95%CI:15-96,N=640),但接种者数量相对较少。
- 对乙型流感未观察到显著保护。
临床怎么用
- 在K亚分支A(H3N2)流行季,两种疫苗对儿童甲型流感仍可提供保护。
- 需继续监测以明确随减毒活疫苗使用增加两种疫苗的比较效果。
局限性
- 减毒活疫苗接种者数量相对较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As part of ongoing surveillance since the 2013/14 season, we evaluated influenza vaccine performance among children in Japan during the 2025/26 season, when subclade K A(H3N2) predominated. A test-negative design was applied to hospitalized febrile children who underwent outpatient influenza testing at 16 hospitals. Among 1033 participants, vaccine uptake among test-negative controls was 38% (274/723) for inactivated influenza vaccine (IIV) and 5% (35/723) for live-attenuated influenza vaccine (LAIV). Adjusted VE against influenza A was estimated at 43% (95% CI: 15-62) for IIV (N = 922) and 81% (95% CI: 15-96) for LAIV (N = 640), although the number of LAIV recipients was relatively small. No significant protection was observed against influenza B. These findings indicate that both vaccines remained effective against influenza A, despite circulation of genetically distinct influenza A viruses. Continued surveillance is warranted to further clarify comparative effectiveness between vaccine types as LAIV uptake increases.
引用
- Shinjoh M, Furuichi M, Sugimoto R, et al. Effectiveness of inactivated and live-attenuated influenza vaccines in children during the 2025-2026 influenza season with genetically distinct influenza A and B viruses. Vaccine. 2026. PMID: 42349133. doi:10.1016/j.vaccine.2026.128869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。